Publications by authors named "N Kleinman"
Objectives: This study investigates the utilization of work absence benefits among United States (US) employees diagnosed with COVID-19, examining frequency, duration, cost, and types of work loss benefits used.
Methods: This retrospective analysis of the Workpartners Research Reference Database (RRDb) included employees eligible for short- and long-term disability (STD and LTD employer-sponsored benefits, respectively), and other paid work absence benefits from 2018 to 2022. Workpartners RRDb includes over 3.
Key Points: Prior research suggests differences in rates of heart failure hospitalization or serious emergency department visits between patients on patiromer versus sodium zirconium cyclosilicate. Total costs of heart failure–related hospitalizations and emergency department visits may be lower in patients on patiromer compared with sodium zirconium cyclosilicate.
Background: Previous work suggested differences between patients taking patiromer or sodium zirconium cyclosilicate (SZC) in real-world risk of heart failure (HF) hospitalizations and edema hospitalizations or emergency department (ED) visits (edema events).
Article Synopsis
- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder that can lead to severe complications like blood clots, kidney failure, and increased mortality due to uncontrolled activity of the immune system.
- A study analyzed data from patients in the Korean National PNH Registry to evaluate how certain factors, especially lactate dehydrogenase (LDH) and hemoglobin levels, impact risks of complications and death in those not treated with complement inhibitors.
- Results showed that high LDH levels and male sex increased the risk of thrombosis, while low hemoglobin did not predict serious outcomes; thus, managing hemolysis in PNH patients could enhance their health results.
Background: In the single-arm CHRYSALIS trial, advanced non-small cell lung cancer patients harboring epidermal growth factor receptor () exon 20 insertion (Exon 20ins) showed durable responses to amivantamab, an EGFR-MET bispecific antibody targeting tumors with Exon 20ins. This study compared the effectiveness of amivantamab to real-world systemic anti-cancer therapies in Japan.
Patients And Methods: External control patients were selected by applying CHRYSALIS eligibility to Japanese patients from LC-SCRUM-Asia.
Research on employee care partners of patients with multiple sclerosis (MS) is limited. The clinical and economic impact on employee care partners was evaluated by MS disease severity. Employees with spouses/domestic partners with MS from the Workpartners database (Jan.
View Article and Find Full Text PDF